$SOHU

Sohu (SOHU) Q2 2026 Earnings Call Transcript

Sohu.com Limited (SOHU) reported Q2 2026 revenue of $136 million, up 7% YoY but down 4% QoQ. Online games were $116 million, up 10% YoY, while marketing services were $15 million. GAAP net income was $0.2 million after a ~$30 million tax reversal; non-GAAP net income was $0.5 million. The company also said it repurchased 9.4M ADS for ~$124M and authorized more up to $150M. Q3 guidance: marketing services $40M-$50M; online games $105M-$150M.

Original reporting
Published Aug 17, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 4:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sohu (SOHU) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$SOHUNeutralMed
01

Why it matters

The key tradable elements are the Q2 earnings improvement driven by a $30M tax reversal, mixed segment revenue trends, and explicit Q3 2026 guidance ranges that imply a sizable year-over-year decline in online game revenues. The board also authorized additional repurchases up to $150M, which can partially offset dilution or sentiment.

02

Market read

This is a primary earnings and guidance disclosure with concrete revenue ranges and a capital return update, likely driving near-term positioning in SOHU.

03

What to watch

Traders may overweight the tax benefit and miss that Changyou segment operating profit rose year over year, while marketing services showed sequential improvement.

Relevance 8/10Novelty 8/10Timing: after-hours earnings call, guidance for Q3 2026 and buyback status disclosed

Background

Sohu.com Limited held its Q2 2026 earnings call, covering continuing operations, segment performance (Sohu Media Platform, Changyou), and capital return via an open-ended share repurchase authorization.

Company-level read

Ticker impact

$SOHUNeutralMedium confidence
Context

Sohu reported Q2 2026 revenue, GAAP/non-GAAP net income after a $30M tax reversal, and provided Q3 2026 segment revenue guidance.

Expected impact

Likely choppy reaction: investors may focus on underlying game revenue decline implied by Q3 guidance versus the one-off tax benefit.

Evidence & confidence

The article includes concrete Q2 results plus explicit Q3 revenue ranges for marketing services and online games, which are the key forward-looking drivers. The tax reversal boosts GAAP/non-GAAP earnings, but the guidance suggests ongoing contraction in online games.

Market effects

Provides a read-through on Chinese online gaming and social media monetization trends, especially the durability of TLBB franchise revenue.

May influence sentiment toward China internet/gaming ADRs based on segment guidance and profitability normalization.

Limited direct global spillover, but can affect risk appetite for small-cap China internet names around earnings season.

Counterpoint

The tax reversal may be viewed as a temporary accounting swing, but the company also cites online game revenues exceeding prior guidance and continued TLBB content updates.

Key entities

  • Sohu.com Limited

    Reported Q2 2026 results, provided Q3 2026 guidance, and disclosed an open-ended share repurchase authorization.

  • Joanna Lv

    CFO who presented segment financials and Q3 2026 revenue and net loss guidance ranges.

Related articles

$SOHUMed

3 Low-P/E Stocks That Look Cheap as the S&P 500 Trades Near Record Highs

Sohu.com (SOHU), Onity Group (ONIT), and TriMas (TRS) trade at low P/E ratios (1.6x, 2.3x, 1.6x respectively) despite showing signs of business strength. SOHU reported 7% YOY revenue growth and improved profitability. ONIT saw 24% YOY revenue growth and 64% origination growth but faced servicing headwinds. TRS showed 1.6% YOY sales growth and 29% operating profit increase, with raised earnings guidance.

$SOHUMed

Sohu.com Q2 Earnings Call Highlights

Sohu.com (NASDAQ:SOHU) reported Q2 call highlights, citing sequential growth in marketing services revenue but a weak advertising environment as advertisers stay cautious and shift toward social and influencer-driven marketing. Management forecast Q3 marketing services revenue of $40M-$50M, online game revenue $105M-$115M, and GAAP/non-GAAP net loss of $30M-$23M. Sohu repurchased 9.4M ADS for about $124M, with up to $150M authorized.

$SOHUMed

Sohu.com Ltd (SOHU): Financial results for Q2 2026

Sohu.com Ltd (SOHU) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 SOHU.COM REPORTS SECOND QUARTER 2026 UNAUDITED FINANCIAL RESULTS BEIJING, Aug 10, 2026 –Sohu.com Limited (NASDAQ: SOHU) (“Sohu” or the “Company”), a leading Chinese online media platform and game business group, today reported unaudited financial results for the seco

$SOHUMedAI 8/10

SOHU.COM REPORTS SECOND QUARTER 2026 UNAUDITED FINANCIAL RESULTS

Sohu.com Limited (NASDAQ: SOHU) reported Q2 2026 unaudited results. Total revenue was $136m, up 7% YoY and down 4% QoQ. GAAP net income was $0.2m after a ~$13m tax expense reversal; non-GAAP net income was $0.5m. The board amended its ADS repurchase program to open-ended; $124m spent on 9.4m ADS as of Aug 6. Q3 guidance: marketing $14m-$15m, online games $105m-$115m, GAAP/non-GAAP net loss $13m-$23m.

$AAPLMed

Asia’s Tech Stocks Take the Hit as Apple and Microsoft Push Chip Costs to Consumers

Apple raised MacBook and iPad prices by up to $300 on June 25, citing higher memory and storage chip costs tied to AI data-center demand; its shares closed down more than 6%. Microsoft followed with Xbox price increases of $100–$150 effective Aug. 1; its stock fell 3.5%. The announcements helped drive an Asian selloff, with South Korea’s KOSPI dropping to about 8,600 early, and chip stocks like SK Hynix and Samsung down over 4%.

$IPHAMed

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma (IPHA) reported Q2 2026 earnings, highlighting a cash position of -€21.4M, a $75M upfront payment from Sobi, and -€28M in net equity proceeds. H1 2026 net loss was -€19.6M, with revenue of -€5.7M. The company extended its cash runway to Q1 2028 and anticipates key milestones, including a Phase 3 readout for monalizumab and initial data for IPH4502. Management expects to file for accelerated approval of lacutamab in Sezary Syndrome in H2 2027.